DK1268509T3 - Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf - Google Patents

Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf

Info

Publication number
DK1268509T3
DK1268509T3 DK01924340.1T DK01924340T DK1268509T3 DK 1268509 T3 DK1268509 T3 DK 1268509T3 DK 01924340 T DK01924340 T DK 01924340T DK 1268509 T3 DK1268509 T3 DK 1268509T3
Authority
DK
Denmark
Prior art keywords
cloning
expression
methods
type
sphingosine kinase
Prior art date
Application number
DK01924340.1T
Other languages
English (en)
Inventor
Sarah Spiegel
Takafumi Kohama
Original Assignee
Daiichi Sankyo Co Ltd
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Univ Georgetown filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of DK1268509T3 publication Critical patent/DK1268509T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK01924340.1T 2000-04-03 2001-03-26 Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf DK1268509T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19431800P 2000-04-03 2000-04-03
US09/817,676 US6800470B2 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
PCT/US2001/009664 WO2001074837A1 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof

Publications (1)

Publication Number Publication Date
DK1268509T3 true DK1268509T3 (da) 2010-03-08

Family

ID=26889896

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01924340.1T DK1268509T3 (da) 2000-04-03 2001-03-26 Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf

Country Status (9)

Country Link
US (4) US6800470B2 (da)
JP (1) JP4584525B2 (da)
KR (1) KR20020093017A (da)
AU (1) AU5100201A (da)
CA (1) CA2404965A1 (da)
DK (1) DK1268509T3 (da)
HU (1) HUP0301691A3 (da)
MX (1) MXPA02009781A (da)
WO (1) WO2001074837A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074837A1 (en) * 2000-04-03 2001-10-11 Sankyo Company, Limited Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
US20030157082A1 (en) * 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
US20060205688A1 (en) * 2002-10-14 2006-09-14 Medvet Science Pty. Ltd. Method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase
WO2004061107A1 (ja) * 2002-12-27 2004-07-22 The New Industry Research Organization スフィンゴシンキナーゼ２を利用した細胞増殖抑制剤、その核移行シグナルを持つ融合タンパク質の作製方法、及び薬剤候補物質のスクリーニング方法、並びにスクリーニングキット
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
WO1999061581A2 (en) * 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
EP1257637A2 (en) * 2000-02-14 2002-11-20 Curagen Corporation Sphingosine kinases
WO2001074837A1 (en) * 2000-04-03 2001-10-11 Sankyo Company, Limited Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof

Also Published As

Publication number Publication date
US7419814B2 (en) 2008-09-02
US20040203104A1 (en) 2004-10-14
JP2004500117A (ja) 2004-01-08
US20020042101A1 (en) 2002-04-11
US6800470B2 (en) 2004-10-05
WO2001074837A1 (en) 2001-10-11
CA2404965A1 (en) 2001-10-11
JP4584525B2 (ja) 2010-11-24
US20120107833A1 (en) 2012-05-03
US8263349B2 (en) 2012-09-11
KR20020093017A (ko) 2002-12-12
US7803595B2 (en) 2010-09-28
HUP0301691A3 (en) 2005-04-28
US20090169555A1 (en) 2009-07-02
AU5100201A (en) 2001-10-15
MXPA02009781A (es) 2004-09-06
HUP0301691A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
DK199900234U4 (da) Paroxetin-methansulfonat i krystallinsk form, farmaceutisk præparat indeholdende dette og andvendelse af forbindelsen til f
DK1268431T3 (da) 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer
DK1144403T3 (da) Substituerede pyrazoler som p38-kinaseinhibitorer
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DK1023050T3 (da) Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
DK1282611T3 (da) Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
NO20032830L (no) Tetrahydropyridinderivater, fremstilling derav og anvendelse som celleproliferasjonsinhibitorer
NO20005454L (no) Nye hydroksyindoler, deres anvendelse som fosfodiesterase 4 inhibitorer og fremgangsmåte for fremstilling derav
NO20024742L (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20031952L (no) 3-aroylinderivater og deres anvendelse som CB2 reseptoragonister
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
DK1263745T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiaxol-2-oner og anvendelse deraf til inhibering af hormonfölsom lipase
DK1265482T3 (da) Vandige formulationer og fremgangsmåde til fremstilling af samme
DK1261697T3 (da) Kuldeaktiv beta-galactosidase, fremgangsmåde til fremstilling heraf og anvendelsen deraf
NO995513D0 (no) N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-A agonister
NO20030848L (no) Paroxetinsammensetninger og fremgangsmåter for å lage det samme
ATE387448T1 (de) 4,5-pyrazinoxindole als proteinkinasehemmer
DK1268509T3 (da) Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf
NO20026103D0 (no) 1-amino-alkylcycloheksaner som 5-HT3 og neuronal nikotinreseptorantagonister
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO20030998L (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler
NO20022969D0 (no) Sammensetninger og metoder for L-nukleosider, L-nukleotider og analoger derav
NO20024105L (no) Memnopeptider, fremgangsmåte for deres fremstilling og anvendelse av disse